Sign in

    Huidong (Gena) Wang

    Managing Director and Senior Equity Research Analyst at Barclays

    Huidong (Gena) Wang is a Managing Director and Senior Equity Research Analyst at Barclays, specializing in Biotechnology and covering a range of companies including BeiGene, Zai Lab, Legend Biotech, and Hutchmed. Recognized for in-depth expertise in the China and global biotech sectors, Wang has delivered investment calls with a success rate above 60% and average returns of over 11% per TipRanks data, placing them among the top biotech analysts on the platform. Wang began their equity research career at Piper Sandler in 2013, focusing on US Emerging Biopharma before moving to Barclays in 2021 to spearhead their Asia ex-Japan Biotech coverage. Professionally credentialed with FINRA Series 7, 63, 86, and 87 licenses, Wang is known for their thorough scientific background and influential insights in the sector.

    Huidong (Gena) Wang's questions to Vir Biotechnology (VIR) leadership

    Huidong (Gena) Wang's questions to Vir Biotechnology (VIR) leadership • Q1 2025

    Question

    Huidong (Gena) Wang asked about the rationale for Alnylam's decision not to opt into the profit-sharing arrangement for elebsiran and inquired about the expected timing for the next data update from VIR's oncology programs.

    Answer

    Marianne De Backer (Executive) explained that Alnylam's decision was based on its own strategic portfolio prioritization and was made before VIR's latest HBV functional cure data was available. Regarding the oncology update, she stated that new data would be shared once more mature results from higher dose levels are available, likely at a future medical congress or a focused investor event.

    Ask Fintool Equity Research AI